Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

August 19th 2021

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Dr. Abida on the Limitations of PARP Inhibitors in Prostate Cancer

August 16th 2021

Wassim Abida, MD, PhD, discusses the limitations of PARP inhibitors in prostate cancer.

Tissue and Liquid Biopsies in Advanced Prostate Cancer

August 16th 2021

Dr Scott T. Tagawa comments on the pros and cons of liquid and tissue biopsies used to assess patients with advanced prostate cancer.

Precision Medicine in Advanced Prostate Cancer

August 16th 2021

A panel of physicians who work in the field of genitourinary oncology comment on the evolving role of precision medicine in advanced prostate cancer.

Dr. Slovin on Considerations for Treatment Selection in Nonmetastatic CRPC

August 11th 2021

Susan F. Slovin, MD, PhD, discusses considerations for treatment selection in nonmetastatic castration-resistant prostate cancer.

Rapid Readouts: Results from the Phase 3 VISION Study

August 11th 2021

A. Oliver Sartor, MD, presents data from the American Society of Clinical Oncology 2021 annual meeting from the VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

PARP Inhibitors, PSMA-Directed Therapy Augment the Prostate Cancer Armamentarium

August 11th 2021

Antiandrogen agents, PARP inhibitors, and prostate-specific membrane antigen-directed therapy have broadened the armamentarium in prostate cancer.

Dr. Danila on Considerations for Treatment Selection in Nonmetastatic CRPC

August 10th 2021

Daniel C. Danila, MD, discusses factors to consider when selecting a treatment option for patients with nonmetastatic castration-resistant prostate cancer.

FDA Finalizes Guidance on MFS as End Point for Prostate Cancer Clinical Trials

August 10th 2021

The FDA has finalized guidance on the use of metastasis-free survival as an end point in clinical trials for nonmetastatic castration-resistant prostate cancer.

Dr. Danila on the Integration of Advanced Imaging in Prostate Cancer

August 9th 2021

Daniel C. Danila, MD, discusses the integration of advanced imaging in prostate cancer.

Future Directions With PSMA Ligand–Directed Therapies

August 6th 2021

Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.

The VISION Study of 177Lu-PSMA-617 in mCRPC

August 6th 2021

Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.

CD38 Expression Linked With Poor OS in Prostate Cancer

August 3rd 2021

The role of CD38 within prostate cancer progression must be further explored, along with CD38-targeting in patients with high-risk disease.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Use of PSMA PET Scans in Advanced Prostate Cancer

July 30th 2021

Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.

Testing for PSMA in Community Settings

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, discusses integration of prostate-specific membrane antigen [PSMA] positron emission tomography [PET] imaging into community practice to help identify potential candidates for PSMA-targeted radioligand therapy.

PSMA-Targeted Radioligand Therapy in Advanced Prostate Cancer

July 30th 2021

Scott T. Tagawa, MD, MS, FACP, reviews implications for treating prostate-specific membrane antigen (PSMA) -positive advanced prostate cancer with lutetium-177–PSMA-617 based on results of the phase III VISION study and additional trials in the pipeline.

Dr. Abida on the Clinical Significance of the TRITON2 Study in mCRPC

July 29th 2021

Wassim Abida, MD, PhD, discusses the clinical significance of the results from the phase 2 TRITON2 trial in metastatic castration-resistant prostate cancer.

Dr. Morris Discusses Ongoing Research With 177Lu-PSMA-617 in Prostate Cancer

July 28th 2021

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Diagnostic and Therapeutic Applications of PSMA in Prostate Cancer

July 28th 2021

An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.